ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000...
-
Upload
gavin-mcdowell -
Category
Documents
-
view
212 -
download
0
Transcript of ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000...
![Page 1: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/1.jpg)
ALZHEIMER'S DISEASE (AD)
Senile dementia. Characterised by amyloid plaques + tau protein
~ 600,000 cases in UK
5% hereditary; 95% spontaneous
Frequent in Down's syndrome (extra chromosome 21)
![Page 2: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/2.jpg)
AD - PLAQUES
From St George-Hyslop (2000)
![Page 3: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/3.jpg)
PLAQUES
-amyloid (A) peptide of 40-43 aas; 42 aa peptide is most toxicdeposits as insoluble precipitate (-sheets)
Nerves associated with plaques degenerate Plaques also associated with 'tangles' of intracellular tau protein
A precursor protein (APP) 770 aasmembrane proteinProcessed in 2 ways. One ( secretase) prevents A formation; the other (-secretase & -secretase) facilitates itgene on chromosome 21hereditary AD - sometimes mutations in APP
![Page 4: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/4.jpg)
APP
-secretase
-secretase+ -secretase
A
PROCESSING OF APP
![Page 5: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/5.jpg)
N
SEVKM DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA TVIVITLVML
-secretase -secretase -secretase
SP cysteine rich acidic KPI OX2 A
lumen cytosol
membrane
AMYLOID PRECURSOR PROTEIN (APP)
Sites of mutations causing AD
![Page 6: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/6.jpg)
INHERITED FORMS OF AD
May involve mutations in :APP (rather rare) presenilins (PS1 and PS2) [50% of hereditary AD has mutations in PS1 or PS2]
PS1 and PS2 membrane proteins (>7 membrane spanning domains)May be involved in signalling and/or apoptosisPart of complex of proteins making up -secretase
![Page 7: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/7.jpg)
PRESENILIN 1 (PS1)
From Hardy (1997)
![Page 8: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/8.jpg)
THE AMYLOID CASCADE HYPOTHESIS
-secretase)
From Mudher & Lovestone (2002)
![Page 9: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/9.jpg)
WHY IS A42 DAMAGING?
1. May disrupt Ca2+ regulation?2. May damage mitochondria with liberation of
oxygen free radicals3. May initiate inflammatory response.
Alternatively: A may have a significant normal physiological role (possibly as an inhibitor of synaptic transmission) and AD results from loss of this.
![Page 10: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/10.jpg)
THE TAU AND TANGLE HYPOTHESIS
From Mudher & Lovestone (2002)
![Page 11: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/11.jpg)
FACTORS THAT INCREASE LIKELIHOOD OF AD
APP mutations
PS-1/2 mutations
Unknown gene on chromosome 10
APOEe4
Head injury
Age
Aluminium ions??
![Page 12: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/12.jpg)
POTENTIAL THERAPIES FOR AD
1. Acetylcholinesterase inhibitors2. Drugs that inhibit - and -secretase3. Immunization against A4. Cholesterol lowering drugs
![Page 13: ALZHEIMER'S DISEASE (AD) Senile dementia. Characterised by amyloid plaques + tau protein ~ 600,000 cases in UK 5% hereditary; 95% spontaneous Frequent.](https://reader036.fdocuments.us/reader036/viewer/2022072006/56649d195503460f949ee311/html5/thumbnails/13.jpg)
-SECRETASE - TARGET FOR THERAPY?
• aspartic protease (homologous to pepsin) - membrane bound
• 3D structure known
• mouse knockout - produces no A; otherwise only slight behavioural effects
• transgenics giving overproduction - increased A
• Peptide inhibitors available, but need small molecule inhibitors that can cross blood-brain barrier